Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,613 people get DNDN articles and Market Currents by email alert.
Get email alerts on DNDN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Dendreon's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 1 Comment
-
Dendreon's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, May 7, 2012 • 12 Comments
-
Dendreon's CEO Discusses Q4 2011 Results - Earnings Conference CallMon, Feb 27, 2012 • 10 Comments
-
Dendreon CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Nov 2, 2011 • 2 Comments
-
Dendreon Corporation Q2 2008 Earnings Call TranscriptWed, Sep 3, 2008
-
Dendreon Corporation Q4 2007 Earnings Call TranscriptMon, Mar 31, 2008
-
Business Wire (May 31, 2013)
-
Business Wire (May 9, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Mar 18, 2013)
-
Business Wire (Mar 12, 2013)
-
Business Wire (Feb 25, 2013)
-
at MarketWatch.com (Jan 11, 2013)
-
at CNBC.com (Jan 11, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Dec 20, 2012)
-
Business Wire (Nov 27, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 2, 2012)
-
at CNBC.com (Oct 29, 2012)
-
Business Wire (Oct 29, 2012)
-
Business Wire (Oct 3, 2012)
DNDN vs. ETF Alternatives
Company Description
Dendreon Corporation (“Dendreon”, the “Company”, “we”, “us”, or “our”), is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, June 13, 2012, 2:34 PM Dendreon (DNDN +19.8%) skyrockets to $7.49/share amidst rumors Sanofi (SNY) is looking to acquire the company for $11/share. Also, Summer Street is starting coverage with a Buy and $18 PT, arguing the Street has "factored in an extremely bear-case scenario" amidst concerns about weaker-than-expected sales of its Provenge prostate cancer drug. It sees Provenge growth and a "turnaround led by new management" driving shares higher. Comment! [Healthcare, On the Move, Quick Ideas, M&A]
- Wednesday, March 21, 2012, 12:26 PM Dendreon (DNDN +3.6%) is rallying, apparently on takeover speculation. The drug developer also jumped last Tuesday on M&A rumors. 1 Comment [Healthcare, M&A, On the Move]
- Wednesday, February 1, 2012, 10:48 AM Savient Pharmaceuticals (SVNT -12.6%) shares plunge after Dendreon (DNDN +4.6%) swipes its CEO, as John Johnson will take the helm at DNDN on June 30 after only one year at SVNT. Deutsche Bank says Johnson has a history of M&A and his fresh perspective might benefit DNDN's near-term strategy, noting his success in selling Imclone to Eli Lilly and attempts to sell SVNT. 2 Comments [Healthcare, On the Move, M&A]
-
Bill Maurer
Update for readers - Will have $GMCR earnings for tomorrow morning. $SODA and $DNDN articles probably coming Monday. - View all 2 replies
-
-
-
- View all 1 replies
-
joe kelly: There is nothing fun about MCP. And a pox on you for reminding me of the worst trade I ever made Mr. Maurer.
-
claycombmichael
$DNDN) Looks like 4.50 was the 2013 bottom for Dendreon. Provenge!! Nothing but upside from here on out...I'm long ( DNDN ) - View all 6 replies
-
McBride: it's 4.10 right now possibly a bounce off the floor, so the resilience is still at around $3.90-$4.50 . I respect your decision to sell. -
McBride: However you may want to follow the 3 day rule next time. Or in the case of this DNDN travesty the 3 YEAR rule. Decide then wait 3 years.
-
claycombmichael
$DNDN has hit it's 2013 Low) Nothing but upside from here on out !! That's Dendreon !! Provenge !! - View all 6 replies
-
claycombmichael: 4.o1 @this time of Day, Reminds me of Gnta) Genta,,, -
McBride: 3.96 this morning, probably on news that Bayer's Algeta (radium-223) will be indicated in the same space as Provenge.
LATEST REPLIES
-
claycombmichael
$DNDN has hit it's 2013 Low) Nothing but upside from here on out !! That's Dendreon !! Provenge !! - View all 6 replies
-
claycombmichael: 4.o1 @this time of Day, Reminds me of Gnta) Genta,,, -
McBride: 3.96 this morning, probably on news that Bayer's Algeta (radium-223) will be indicated in the same space as Provenge.
-
claycombmichael
$DNDN) Looks like 4.50 was the 2013 bottom for Dendreon. Provenge!! Nothing but upside from here on out...I'm long ( DNDN ) - View all 6 replies
-
McBride: it's 4.10 right now possibly a bounce off the floor, so the resilience is still at around $3.90-$4.50 . I respect your decision to sell. -
McBride: However you may want to follow the 3 day rule next time. Or in the case of this DNDN travesty the 3 YEAR rule. Decide then wait 3 years.
-
Bill Maurer
Update for readers - Will have $GMCR earnings for tomorrow morning. $SODA and $DNDN articles probably coming Monday. - View all 2 replies
-
-
-
- View all 1 replies
-
joe kelly: There is nothing fun about MCP. And a pox on you for reminding me of the worst trade I ever made Mr. Maurer.
-
- View all 2 replies
-
theWinner4Us: copper prices are crashing were headed for a double dip"7/29/12 -
jimmy4winners: Looks for now a rebound the the new trillion coin will stabe the markets USG, Ford ,,both look great!!
-
- View all 4 replies
-
VFC's Stock House: Haha, SmokeyRose - I don't know much more than anyone else, except that $INO is up about twenty five percent this year. Nice. Good luck! -
-
- View all 1 replies
-
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
-
- View all 2 replies
-
-
dave staggs: Keep in mind that this is a last resort drug. Meaning, if this doesn't work, the patient dies. Ins Co's going to get sued if deny.
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-




